Healthy Living/WellnessNovartis drug LCZ696 for treating heart failure, promises to be a blockbuster An experimental heart failure drug developed by Novartis shows potential to become a blockbuster drug. In a trial, LCZ696 has reduced cardiovascular-related deaths by 20 percent compared with an older drug.by Rhodi Lee
Healthy Living/WellnessSanofi-Regeneron drug alirocumab seen reducing bad cholesterol (LDL) to huge extentby Rhodi Lee
Healthy Living/WellnessLow carb diet better than low fat diet for weight loss, good heartby Rhodi Lee
Healthy Living/WellnessExperimental Novartis drug may reduce heart failure deaths, study revealsby Linda Nguyen
Healthy Living/WellnessExperimental Ebola drug ZMapp cures monkeys in clinical trial: Humans, next?by Linda Nguyen
Healthy Living/WellnessUse of recreational marijuana leads to more traffic deaths? Researchers remain dividedby James Maynard
Healthy Living/WellnessKraft recalls 7,691 cases of single slice American cheese over premature spoilage/food-borne illness concernsby Jim Algar
Healthy Living/WellnessSanofi, Regeneron experimental drug lowers risk of stroke, heart attackby Dianne Depra